Stefano Cascinu1, György Bodoky2, Kei Muro3, Eric Van Cutsem4, Sang Cheul Oh5, Gunnar Folprecht6, Sumitra Ananda7, Gustavo Girotto8, Zev A Wainberg9, Maria Luisa Limon Miron10, Jaffer Ajani11, Ran Wei12, Astra M Liepa13, Roberto Carlesi13, Michael Emig13, Atsushi Ohtsu14. 1. Department of Oncology and Hematology, Modena University Hospital, University of Modena and Reggio Emilia, Modena, Italy. 2. Department of Oncology, St. Laszlo Hospital, Budapest, Hungary. 3. Aichi Cancer Center Hospital, Aichi, Japan. 4. Gastroenterology/Digestive Oncology, University Hospitals Gasthuisberg Leuven and KULeuven, Leuven, Belgium. 5. Korea University Guro Hospital, Seoul, Republic Of Korea. 6. Universitätsklinikum Carl Gustav Carus, Dresden, Germany. 7. Western Health, Melbourne, Australia. 8. Faculdade de Medicina, Hospital de Base, São Paulo, Brazil. 9. University of California Los Angeles, California, USA. 10. Hospital Universitario Virgen del Rocío, Sevilla, Spain. 11. University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 12. Statistics, Eli Lilly and Company, Indianapolis, Indiana, USA. 13. Oncology, Eli Lilly and Company, Indianapolis, Indiana, USA. 14. National Cancer Center Hospital East, Chiba, Japan.
Abstract
BACKGROUND: In the intent-to-treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with symptom palliation. MATERIALS AND METHODS:Tumor response was assessed with RECIST v1.1, and quality of life (QoL) was assessed with the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) v3.0. Prespecified and post hoc analyses were conducted in the ITT population, patients with measurable disease, or responders, and included best overall response (BOR), ORR, disease control rate (DCR), duration of response, time to response (TtR), change in tumor size, and associations of QoL with tumor shrinkage and BOR. RESULTS: In both treatment arms, median TtR was 1.5 months. Responses were more durable in the ramucirumab versus control arm (median 4.4 vs. 2.8 months). In patients with measurable disease (78% of ITT), ORR was 36% versus 20%; DCR was 81% versus 61% in the ramucirumab versus control arms. Waterfall plots demonstrated more tumor shrinkage in the ramucirumab versus control arm. Regardless of treatment, tumor response and stable disease were associated with improved or stable QoL, with more tumor shrinkage associated with greater symptom palliation. CONCLUSION: Treatment with ramucirumab plus paclitaxel yielded the highest ORR reported to date for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. Additional details demonstrate robustness of tumor response results. The extent of tumor shrinkage is directly associated with symptom palliation and should be considered when evaluating patient needs and treatment selection. Clinical trial identification number. NCT01170663. IMPLICATIONS FOR PRACTICE: Ramucirumab plus paclitaxel is a recognized standard of care as it improves survival for patients with advanced gastric or gastroesophageal junction adenocarcinoma who have been previously treated with recommended first-line therapy. These additional data on tumor response demonstrate a positive association between tumor shrinkage and symptom palliation in a patient population that is often symptomatic. These observations included patients with nonmeasurable disease, a group of patients often underrepresented in clinical trials. This knowledge can inform treatment decisions, which align individual patient characteristics and needs with demonstrated benefits.
RCT Entities:
BACKGROUND: In the intent-to-treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with symptom palliation. MATERIALS AND METHODS:Tumor response was assessed with RECIST v1.1, and quality of life (QoL) was assessed with the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) v3.0. Prespecified and post hoc analyses were conducted in the ITT population, patients with measurable disease, or responders, and included best overall response (BOR), ORR, disease control rate (DCR), duration of response, time to response (TtR), change in tumor size, and associations of QoL with tumor shrinkage and BOR. RESULTS: In both treatment arms, median TtR was 1.5 months. Responses were more durable in the ramucirumab versus control arm (median 4.4 vs. 2.8 months). In patients with measurable disease (78% of ITT), ORR was 36% versus 20%; DCR was 81% versus 61% in the ramucirumab versus control arms. Waterfall plots demonstrated more tumor shrinkage in the ramucirumab versus control arm. Regardless of treatment, tumor response and stable disease were associated with improved or stable QoL, with more tumor shrinkage associated with greater symptom palliation. CONCLUSION: Treatment with ramucirumab plus paclitaxel yielded the highest ORR reported to date for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. Additional details demonstrate robustness of tumor response results. The extent of tumor shrinkage is directly associated with symptom palliation and should be considered when evaluating patient needs and treatment selection. Clinical trial identification number. NCT01170663. IMPLICATIONS FOR PRACTICE: Ramucirumab plus paclitaxel is a recognized standard of care as it improves survival for patients with advanced gastric or gastroesophageal junction adenocarcinoma who have been previously treated with recommended first-line therapy. These additional data on tumor response demonstrate a positive association between tumor shrinkage and symptom palliation in a patient population that is often symptomatic. These observations included patients with nonmeasurable disease, a group of patients often underrepresented in clinical trials. This knowledge can inform treatment decisions, which align individual patient characteristics and needs with demonstrated benefits.
Authors: Hugo E R Ford; Andrea Marshall; John A Bridgewater; Tobias Janowitz; Fareeda Y Coxon; Jonathan Wadsley; Wasat Mansoor; David Fyfe; Srinivasan Madhusudan; Gary W Middleton; Daniel Swinson; Stephen Falk; Ian Chau; David Cunningham; Paula Kareclas; Natalie Cook; Jane M Blazeby; Janet A Dunn Journal: Lancet Oncol Date: 2013-12-10 Impact factor: 41.316
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Sun Jin Sym; Junshik Hong; Jinny Park; Eun Kyung Cho; Jae Hoon Lee; Yeon Ho Park; Woon Ki Lee; Min Chung; Hyung-Sik Kim; Se Hoon Park; Dong Bok Shin Journal: Cancer Chemother Pharmacol Date: 2012-11-29 Impact factor: 3.333
Authors: S-E Al-Batran; E Van Cutsem; S C Oh; G Bodoky; Y Shimada; S Hironaka; N Sugimoto; O N Lipatov; T-Y Kim; D Cunningham; P Rougier; K Muro; A M Liepa; K Chandrawansa; M Emig; A Ohtsu; H Wilke Journal: Ann Oncol Date: 2016-01-07 Impact factor: 32.976